Compare AMWL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | STRO |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.4M | 94.9M |
| IPO Year | 2020 | 2018 |
| Metric | AMWL | STRO |
|---|---|---|
| Price | $3.96 | $8.50 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $8.33 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 109.3K | 108.6K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $265,023,000.00 | $105,646,000.00 |
| Revenue This Year | N/A | $62.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $5.23 |
| 52 Week High | $12.95 | $30.10 |
| Indicator | AMWL | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 86.62 |
| Support Level | $3.98 | $0.72 |
| Resistance Level | $4.22 | $9.38 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | 0.07 | 0.96 |
| Stochastic Oscillator | 51.85 | 90.29 |
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.